ArticleFrontiers in pharmacology2021
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05077332 (Leidos-Enabled Adaptive Protocol for Clinical Trials), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.Digestive diseases and sciences · 2021Pooled it
- Histamine receptors and COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Pooled it
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Role of HWorld journal of clinical cases · 2022Trial
- Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial.American journal of therapeuticsTrial
- Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID.Cureus · 2025Review
- Famotidine increases cellular phospho-tyrosine levels.Biochemical and biophysical research communications · 2024Article
- Unraveling the relevance of SARS-Cov-2 infection and ferroptosis within the heart of COVID-19 patients.Heliyon · 2024Article
- Human Lung Mast Cells as a Possible Reservoir for Coronavirus: A Novel Unrecognized Mechanism for SARS-CoV-2 Immune-Mediated Pathology.International journal of molecular sciences · 2024Article
- Mast cell degranulation-triggered by SARS-CoV-2 induces tracheal-bronchial epithelial inflammation and injury.Virologica Sinica · 2024Article
- Postacute Sequelae of SARS-CoV-2 in Children.Pediatrics · 2024Review
- Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study.Metabolites · 2023Article
- Mast cell activation may contribute to adverse health transitions in COVID-19 patients with frailty.Emerging microbes & infections · 2023Article
- A retrospective analysis of clinical outcomes between hospitalized patients with COVID-19 who received famotidine or pantoprazole.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- The pathophysiology of postacute sequelae of COVID-19 (PASC): Possible role for persistent inflammation.Asia Pacific allergy · 2023Review
- Effectiveness of famotidine on the risk of poor prognosis in patients with COVID-19: A nationwide cohort study in Korea.Heliyon · 2023Article
- Antihistamines as an early treatment for Covid-19.Heliyon · 2023Article
- Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.Journal of Korean medical science · 2023Article
- A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.Healthcare (Basel, Switzerland) · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
25 authors at 10 institutions in 2 countries.
Funding
Abstract
SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We have investigated several plausible hypotheses for famotidine activity including antiviral and host-mediated mechanisms of action. We propose that the principal mechanism of action of famotidine for relieving COVID-19 symptoms involves on-target histamine receptor H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.